170 related articles for article (PubMed ID: 36499357)
1. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
2. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
3. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
5. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
[TBL] [Abstract][Full Text] [Related]
6. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
8. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
9. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.
Gaonkar RH; Schmidt YT; Mansi R; Almeida-Hernandez Y; Sanchez-Garcia E; Harms M; Münch J; Fani M
J Med Chem; 2023 Jul; 66(13):8484-8497. PubMed ID: 37328158
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of the Peptide CXCR4-Antagonist on Macromolecular and Supramolecular Protraction Arms Affords Increased Potency and Enhanced Plasma Stability.
Harms M; Hansson RF; Carmali S; Almeida-Hernández Y; Sanchez-Garcia E; Münch J; Zelikin AN
Bioconjug Chem; 2022 Apr; 33(4):594-607. PubMed ID: 35293739
[TBL] [Abstract][Full Text] [Related]
12. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
[TBL] [Abstract][Full Text] [Related]
13. Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy.
Schauenburg D; Zech F; Heck AJ; von Maltitz P; Harms M; Führer S; Alleva N; Münch J; Kuan SL; Kirchhoff F; Weil T
Bioconjug Chem; 2023 Sep; 34(9):1645-1652. PubMed ID: 37665137
[TBL] [Abstract][Full Text] [Related]
14. EPI-X4, a novel endogenous antagonist of CXCR4.
Buske C; Kirchhoff F; Münch J
Oncotarget; 2015 Nov; 6(34):35137-8. PubMed ID: 26459389
[No Abstract] [Full Text] [Related]
15. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
16. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
17. Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4
Cano-Garrido O; Álamo P; Sánchez-García L; Falgàs A; Sánchez-Chardi A; Serna N; Parladé E; Unzueta U; Roldán M; Voltà-Durán E; Casanova I; Villaverde A; Mangues R; Vázquez E
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208189
[TBL] [Abstract][Full Text] [Related]
18. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
19. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
Stalmeijer EH; Van Rij RP; Boeser-Nunnink B; Visser JA; Naarding MA; Schols D; Schuitemaker H
J Virol; 2004 Mar; 78(6):2722-8. PubMed ID: 14990692
[TBL] [Abstract][Full Text] [Related]
20. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
